Peroxisome proliferator‐activated receptor δ agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis
Saravanan Kanakasabai(IST Research), John J. Bright(IST Research), Wade T. Iams(Centerstone), Suzanne M. Adams(IST Research), Crystal C. Walline(IST Research), Wanida Chearwae(IST Research)
Cited by 83
Related Papers
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
|Journal for ImmunoTherapy of Cancer|2018|468
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459
Immunotherapeutic approaches for small-cell lung cancer
|Nature Reviews Clinical Oncology|2020|346
Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)
|Scientific Reports|2018|258
Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade
|Clinical Cancer Research|2015|178